MIMEDX to Host Third Quarter 2022 Operating and Financial Results Conference Call on November 2

Rhea-AI Summary

MiMedx Group, Inc. (MDXG) will report its third-quarter financial results for the period ended September 30, 2022, after market close on November 2, 2022. The company's management will host a conference call and webcast at 5:00 p.m. ET that day to discuss the results. MiMedx specializes in placental biologics and has supplied over two million allografts to address acute and chronic non-healing wounds. The company utilizes proprietary methods, including the PURION® process, to produce its allografts.

Positive

• Developing and distributing placental tissue allografts with proprietary processes.
• Pioneer in placental tissue engineering with a commercial business model.
• Over two million allografts supplied, indicating strong market presence.

Negative

• None.

MARIETTA, Ga., Oct. 19, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the third quarter ended September 30, 2022, after the market close on Wednesday, November 2, 2022. The MIMEDX senior management team will host a webcast and conference call to review its results on the same day, beginning at 5:00 p.m. Eastern Time.

The conference call can be accessed using the following information:

Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13733025

A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.

About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contact:
Investors
Matt Notarianni
470-304-7291 
mnotarianni@mimedx.com

 

FAQ

When will MiMedx report its financial results for Q3 2022?

MiMedx will report its financial results for the third quarter on November 2, 2022.

What time will the MiMedx conference call take place?

The MiMedx conference call will begin at 5:00 p.m. Eastern Time on November 2, 2022.

How can I access the MiMedx Q3 2022 conference call?

The conference call can be accessed via webcast or by calling U.S. Investors at 877-407-6184 or International Investors at 201-389-0877.

What services does MiMedx provide?

MiMedx develops and distributes placental tissue allografts for various healthcare needs, focusing on non-healing wounds and degenerative musculoskeletal conditions.